{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:41:33Z","timestamp":1794645693985,"version":"4.9.1"},"reference-count":29,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T00:00:00Z","timestamp":1147392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Non\u2010alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver injury. Currently, there are no proven effective therapies available. Atorvastatin is a new 3\u2010hydroxy\u20103\u2010metylglutaryl coenzyme A reductase inhibitor that reduces lipid serum levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the effectiveness and safety of atorvastatin in dyslipemid, non\u2010alcoholic fatty liver patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We prospectively enrolled 25 patients with NAFLD; 22 of them completed the study. Body mass index, serum lipids, liver function tests and liver density assessed by echography were measured at baseline and after 1, 3, 6, 9 and 12\u2003months of treatment. Normalization of transaminases and\/or improvement in liver density were treatment end points. Patients received atorvastatin (10\u201380\u2003mg\/daily) according to basal serum choleresterol levels; additionally, they were given standard weight\u2010loss counselling and encouraged to follow a low fat diet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All 22 patients (14 men, mean age 47\u2003\u00b1\u200310\u2003years) had high cholesterol levels at baseline and 11 (44%) also presented high trygliceride levels. After 6\u2003months of treatment, eight patients (36.3%) presented normal transaminase levels. The remaining patients continued treatment for 12\u2003months when 20% of patients presented with normal transaminase levels, while the other patients showed a 10% reduction in basal levels. Mean cholesterol levels were 268.5\u2003\u00b1\u200344.2 and 186.8\u2003\u00b1\u200314.4\u2003mg\/dL before and after treatment, respectively (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). The mean body mass index was 27.4\u2003\u00b1\u20033.1 at baseline and 26.3\u2003\u00b1\u20032.8\u2003kg\/cm<jats:sup>2<\/jats:sup>at the end of treatment (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030.05). No side effects were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Serum aminotransferase and lipid levels were reduced significantly in all patients with atorvastatin treatment. Therapy with atorvastatin in NAFLD patients with hyperlipidemia was found to be both effective and safe.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.02926.x","type":"journal-article","created":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T15:44:58Z","timestamp":1147448698000},"page":"1643-1647","source":"Crossref","is-referenced-by-count":154,"title":["A pilot study of atorvastatin treatment in dyslipemid, non\u2010alcoholic fatty liver patients"],"prefix":"10.1111","volume":"23","author":[{"given":"E.","family":"G\u00d3MEZ\u2010DOM\u00cdNGUEZ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"GISBERT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"MORENO\u2010MONTEAGUDO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"GARC\u00cdA\u2010BUEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"MORENO\u2010OTERO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,5,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Non\u2010alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig J","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00450.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-2-199701150-00008"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02334.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02012.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840400411"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36569"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.022"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90235-6"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290347"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02751.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70506-8"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.8.2057"},{"issue":"2","key":"e_1_2_6_15_2","first-page":"17","article-title":"Review article: the treatment of fatty liver disease associated with the metabolic syndrome","volume":"22","author":"Marchesini G","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.17894"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80287-5"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(91)90942-5"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-12931"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.2.427"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2003.70"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00714-0"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5085(01)82704-9","article-title":"Atorvastatin for the treatment of NASH","volume":"120","author":"Harlander JC","year":"2001","journal-title":"Gastroenterology"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1155\/2003\/857869"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200209000-00011"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840110114"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(05)80350-2"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(03)00024-2"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.1.150.34803"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00464-1"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.02926.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.02926.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:21:41Z","timestamp":1736378501000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.02926.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,12]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1365-2036.2006.02926.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02926.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,12]]}}}